Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$1.2 million.

  • Corvus Pharmaceuticals' Change in Account Payables fell 27621.21% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101000.0, marking a year-over-year decrease of 7846.48%. This contributed to the annual value of $1.1 million for FY2024, which is 33436.81% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Change in Account Payables of -$1.2 million as of Q3 2025, which was down 27621.21% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Change in Account Payables peaked at $1.8 million during Q2 2025, and registered a low of -$2.3 million during Q4 2022.
  • Over the past 4 years, Corvus Pharmaceuticals' median Change in Account Payables value was $121000.0 (recorded in 2023), while the average stood at $27266.7.
  • Within the past 5 years, the most significant YoY rise in Corvus Pharmaceuticals' Change in Account Payables was 56186.87% (2025), while the steepest drop was 161666.67% (2025).
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Change in Account Payables stood at -$2.3 million in 2022, then surged by 105.38% to $121000.0 in 2023, then soared by 485.95% to $709000.0 in 2024, then tumbled by 264.03% to -$1.2 million in 2025.
  • Its Change in Account Payables stands at -$1.2 million for Q3 2025, versus $1.8 million for Q2 2025 and -$1.3 million for Q1 2025.